Find Clinical Trials
Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris (ASSOCIATE)
Servier Protocol Code:
CL3-16257-057
Sponsor:
Institut de Recherches Internationales Servier
Clinicaltrials.gov Identifier:
NCT00202566
EudraCT Number:
2004-001960-30
Find a recruiting site
How to participate in this study
If you think you are eligible for this study (see
below), you can identify the location closest to you and contact them directly. If you can’t find a location close to you, please contact Institut de Recherches Internationales Servier (I.R.I.S.)
eligibility criteria
Researchers look for people who fit a certain decription, called eligibility criteria. These include inclusion criteria and exclusion criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
The study has 1 location
Study description
To test whether ivabradine when given in combination with atenolol is able to improve the exercise tolerance of patients with stable angina pectoris
Official title: Evaluation of the Anti-anginal Efficacy and Safety of Oral Administration of Ivabradine Compared to Placebo on Top of Background Therapy With Atenolol in Patients With Stable Angina Pectoris. A Four-month Randomised Double-blind, Parallel Group International Multicentre Study.
Results
English (USA)Conditions
Angina Pectoris
Interventions / Treatments
The treatment(s) given to the participants in the study.
- Ivabradine
Other study id numbers
Other identification numbers the study may be known by.
- CL3-16257-057
Eligibility Criteria
Researchers look for people who fit a certain decription, called eligibility criteria. These include inclusion criteria and exclusion criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligible age for the study
18 years to 75 years
(Adult, Older Adult)
Sex
Male/FemaleAccepts Healthy Volunteers
No- * Chronic stable angina pectoris
- * Documented coronary artery disease
- * Previous treatment with atenolol or other beta-blocker agent
- * Exercise tolerance test positivity and stability
- * Heart rate < 60 bpm
- * Congestive heart failure
How is the study designed?
Allocation
How participants are assigned to different groups. Allocation can be random (randomized) or predetermined (non-randomized). Randomized means that participants are assigned at random to their participant group / arm.
Interventional study model
How treatments are given and tested in a study.
Parallel
A parallel study design compares two or more groups at the same time, with each group receiving a different treatment. Researchers then compare the results to determine which treatment is more effective.
Keywords
Additional Relevant MeSH Terms Glioma
Angina Pectoris